NasdaqGS - Nasdaq Real Time Price USD

Anika Therapeutics, Inc. (ANIK)

Compare

15.57

-0.37

(-2.32%)

At close: January 10 at 4:00:02 PM EST

15.57

0.00

(0.00%)

After hours: January 10 at 4:01:12 PM EST

We Think Anika Therapeutics (NASDAQ:ANIK) Can Easily Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Simply Wall St. 11 days ago

ANIK
-2.32%
Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference

BEDFORD, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET. Management will also participate in one-on-one investor meetings throughout the event. The presentation will be webcast live on

GlobeNewswire 18 days ago

ANIK
-2.32%
Sidoti Events, LLC's Virtual December Small-Cap Conference

NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day December Small-Cap Conference taking place Wednesday and Thursday, December ...

ACCESSWIRE last month

GCTS

GCTS-WS

PTHRF
Anika To Participate in December 2024 Investor Conferences

BEDFORD, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that senior management will participate in the following upcoming conferences. 36th Annual Piper Sandler Healthcare Conference in New York, NY on December 3rd. Dr. Cheryl Blanchard, President and CEO of Anika and Steve Griffin, Executive Vice President and Chief Financial Officer, are scheduled to present at 10:30am ET.

GlobeNewswire last month

ANIK
-2.32%
Anika Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Anika Therapeutics ( NASDAQ:ANIK ) Third Quarter 2024 Results Key Financial Results Revenue: US$38.8m (down 6.5% from...

Simply Wall St. 2 months ago

ANIK
-2.32%
Anika Therapeutics Inc (ANIK) Q3 2024 Earnings Call Highlights: Strategic Shifts Amid Revenue ...

Anika Therapeutics Inc (ANIK) navigates revenue challenges with a focus on HA-based products and international growth.

GuruFocus.com 2 months ago

ANIK
-2.32%
Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics

Executive management from Primo Medical Group along with others, combined to acquire Arthrosurface, Inc., a leading provider of joint restoration and preservation solutions for active patients, from Anika Therapeutics (NASDAQ: ANIK). Two former Arthrosurface leaders joined the Primo Medical Group executives in this strategic acquisition which ensures that Arthrosurface's position as a leader in orthopedic joint preservation solutions will resume with its portfolio of innovative products and expe

PR Newswire 2 months ago

ANIK
-2.32%
Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates

Anika (ANIK) delivered earnings and revenue surprises of -183.33% and 8.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

ANIK
-2.32%
Anika: Q3 Earnings Snapshot

ANIK) on Thursday reported a loss of $29.9 million in its third quarter. On a per-share basis, the Bedford, Massachusetts-based company said it had a loss of $2.03. Losses, adjusted for asset impairment costs and stock option expense, were 25 cents per share.

Associated Press Finance 2 months ago

ANIK
-2.32%
Anika Reports Third Quarter 2024 Financial Results

Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds Strategy to focus on market leading OA Pain Management and high-growth Regenerative Solutions Company to categorize revenue into OEM Channel and Commercial Channel; Commercial Channel remains on track to achieve ~17% CAGR since 2021 with recent performance fueled by the IntegrityTM Implant System

GlobeNewswire 2 months ago

ANIK
-2.32%
Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical

Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth ProfileBEDFORD, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced the divestiture of its Arthrosurface business and the intention to divest of the Parcus Medical business. These decisions are the result of the

GlobeNewswire 2 months ago

ANIK
-2.32%
Investors in Anika Therapeutics (NASDAQ:ANIK) have unfortunately lost 61% over the last five years

Statistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can...

Simply Wall St. 2 months ago

ANIK
-2.32%
Anika Announces Third Quarter 2024 Results Conference Call Date

BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024 financial results before the opening of the market on Thursday, October 31, 2024, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (in

GlobeNewswire 2 months ago

ANIK
-2.32%
Anika Therapeutics Inc (ANIK) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

Anika Therapeutics Inc (ANIK) reports mixed results with a focus on international expansion and new product launches to offset domestic market headwinds.

GuruFocus.com 3 months ago

ANIK
-2.32%
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on October 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 6,350 shares of common stock at a per share exercise price of $24.27, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-execu

GlobeNewswire 3 months ago

ANIK
-2.32%
Anika Therapeutics, Inc. (NASDAQ:ANIK) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Anika Therapeutics, Inc. ( NASDAQ:ANIK ) came out with its quarterly results last week, and we wanted to see how the...

Simply Wall St. 4 months ago

ANIK
-2.32%
Anika Therapeutics, Inc. (ANIK): Are Hedge Funds Bullish on This Caligan Partners-Approved Stock?

We recently compiled a list of the Top 10 Holdings of Caligan Partners. In this article, we are going to take a look at where Anika Therapeutics, Inc. (NASDAQ:ANIK) stands against Caligan Partners’ other top holdings. Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds. David Johnson is the brainchild behind […]

Insider Monkey 5 months ago

ANIK
-2.32%
^GSPC
Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates

Anika (ANIK) delivered earnings and revenue surprises of -26.09% and 5.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

ANIK
-2.32%
Anika: Q2 Earnings Snapshot

BEDFORD, Mass. AP) — Anika Therapeutics Inc. ANIK) on Thursday reported a loss of $88,000 in its second quarter.

Associated Press Finance 5 months ago

ANIK
-2.32%
Anika Reports Second Quarter 2024 Financial Results

Expanded Regenerative Solutions portfolio with full market release of the Integrity™ Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand Delivered revenue in line with expectations with 15% adjusted EBITDA margins; Strong first half 2024 international OA Pain Management revenue growth of 17% Enhanced capital allocation strategy with new $40 million share repurchase program announced in May 2024; Continuing to optim

GlobeNewswire 5 months ago

ANIK
-2.32%

Performance Overview

Return	ANIK	S&P 500
YTD	-4.18%	-1.35%
1-Year	-30.65%	+22.51%
3-Year	-54.69%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Anika Therapeutics, Inc. (ANIK)

We Think Anika Therapeutics (NASDAQ:ANIK) Can Easily Afford To Drive Business Growth

Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference

Sidoti Events, LLC's Virtual December Small-Cap Conference

Anika To Participate in December 2024 Investor Conferences

Anika Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Anika Therapeutics Inc (ANIK) Q3 2024 Earnings Call Highlights: Strategic Shifts Amid Revenue ...

Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics

Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates

Anika: Q3 Earnings Snapshot

Anika Reports Third Quarter 2024 Financial Results

Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical

Investors in Anika Therapeutics (NASDAQ:ANIK) have unfortunately lost 61% over the last five years

Anika Announces Third Quarter 2024 Results Conference Call Date

Anika Therapeutics Inc (ANIK) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Therapeutics, Inc. (NASDAQ:ANIK) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Anika Therapeutics, Inc. (ANIK): Are Hedge Funds Bullish on This Caligan Partners-Approved Stock?

Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates

Anika: Q2 Earnings Snapshot

Anika Reports Second Quarter 2024 Financial Results

Performance Overview